Publication of a Supplementary Prospectus

RNS Number : 3529G
Marwyn Acquisition Company III Ltd
14 November 2022
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, ANY MEMBER STATE OF THE EUROPEAN ECONOMIC AREA OR ANY JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

LEI:  254900YT8SO8JT2LGD15

Marwyn Acquisition Company III Limited (the "Company")

Publication of a Supplementary Prospectus

Further to the Company's announcement on 7 November 2022, the Company today announces the publication of a supplementary prospectus following the appointments of Antoinette Vanderpuije and Tom Basset as directors of the Company and the resignation of Mark Brangstrup Watts as a director of the Company.

The supplementary prospectus is supplemental to, and should be read in conjunction with, the prospectus published by the Company on 29 April 2022 in relation to a placing programme of up to 500 million C shares of £1.00 each. 

A copy of the supplementary prospectus will shortly be available for inspection at  https://data.fca.org.uk/#/nsm/nationalstoragemechanism  and is available on the Company's website https://www.marwynac3.com/investors/prospectus/ .

Enquiries:

Company Secretary

Antoinette Vanderpuije - 020 7004 2700

Marwyn Acquisition Company III Limited, 11 Buckingham Street, London, WC2N 6DF

Finsbury - PR Adviser

Rollo Head 07768 994 987

Chris Sibbald 07855 955 531

Investec Bank plc - Financial Adviser 020 7597 5970

Chris Baird

Carlton Nelson

Alex Wright

N.M. Rothschild & Sons Limited - Financial Adviser 020 7280 5000

Peter Nicklin

Shannon Nicholls

WH Ireland - Corporate Broker 020 7220 1666

Harry Ansell

Katy Mitchell

IMPORTANT INFORMATION:

This announcement has been prepared by, and is the sole responsibility of, the Directors of Marwyn Acquisition Company III Limited.

This announcement does not constitute a prospectus relating to the Company and does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for, any shares in the Company in any jurisdiction nor shall it, or any part of it, or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement to enter into, any contract therefor. The prospectus is, and when published the supplementary prospectus will be, available from the Company's website at  https://www.marwynac3.com/investors/prospectus/ .

Neither the content of the Company's website, nor the content on any website accessible from hyperlinks on its website for any other website, is incorporated into, or forms part of, this announcement nor, unless previously published by means of a recognised information service, should any such content be relied upon in reaching a decision as to whether or not to acquire, continue to hold, or dispose of, securities in the Company.

Notes

Company Background

Marwyn Acquisition Company III ("MAC III") is an acquisition vehicle listed on the standard segment of the London Stock Exchange. The Company is backed by Marwyn who have launched 11 previous comparable acquisition vehicles that have acquired platform businesses, which include Advanced Computer Software, BCA Marketplace, Breedon Aggregates and Entertainment One. More information on MAC III can be found here: www.marwynac3.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PSPUSANRURUAAAA
UK 100

Latest directors dealings